28 episodes
Explore Cell Therapy National Marrow Donor Program/Be The Match
-
- Education
-
-
5.0 • 1 Rating
-
In Explore Cell Therapy, we dig into the latest cell and gene therapy research and best practices to help you advance care for patients with hematologic malignancies and disorders. You’ll hear interviews with well-known and up-and-coming physicians in the hematopoietic stem cell transplantation (HCT) and cell and gene therapy field. You’ll receive insights from the National Marrow Donor Program®/Be The Match® and our partners into what it takes to connect patients to the best available therapies.
In season 2, we examine practice-changing research and hot topics in HCT and other cellular therapies. You’ll hear conversations with experts who specialize in HCT and at community hematology/oncology practices.
-
10 – Trends in HCT Equity, Access and Outcomes, Pt. 2: Personalization and Future Care
In this two-part episode, Rachel Phelan, MD, MPH, with the Medical College of Wisconsin and Rafeek Yusuf, MD, PhD, with NMDP discuss the latest trends in access and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation according to their recent CIBMTR (Center for International Blood and Marrow Transplant Research) report.
In Part II: Personalization and Future Care, guests highlight the importance of holistic, personalized care throughout the patient journey as we navigate the complexities of transplantation, advocate for precision medicine, and envision a future with even more inclusive and effective health care solutions.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. -
10 – Trends in HCT Equity, Access and Outcomes, Pt. 1: Improvements and Challenges
In this two-part episode, Rachel Phelan, MD, MPH, with the Medical College of Wisconsin and Rafeek Yusuf, MD, PhD, with NMDP discuss the latest trends in access and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation according to their recent CIBMTR (Center for International Blood and Marrow Transplant Research) report.
In Part I: Improvements and Challenges, experts illuminate significant strides in GVHD prevention and the use of haploidentical and mismatched unrelated donor sources to close gaps in equity. We explore the multifaceted barriers hindering equitable transplantation – from socioeconomic and health literacy challenges to donor availability.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. -
09 – A New Era of GVHD Prevention Post-HCT, Pt. 2: Progressive Research and the Future of Care
In this two-part episode, Javier Bolaños-Meade, MD, with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Shernan Holtan, MD, with the University of Minnesota discuss advances and innovations in graft-versus-host disease (GVHD) prevention that call for a new standard of care in patients needing allogeneic hematopoietic cell transplantation.
In Part II: Progressive Research and the Future of Care, guests dive deeper into the results of their recently published clinical trial outlining a novel drug combination for GVHD prevention, address the importance of ongoing communication, and take a look at how research is continuing to progress to promote a new standard of care.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. -
09 – A New Era of GVHD Prevention Post-HCT, Pt. 1: PTCy and Improved Outcomes
In this two-part episode, Javier Bolaños-Meade, MD, with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Shernan Holtan, MD, with the University of Minnesota discuss advances and innovations in graft-versus-host disease (GVHD) prevention that call for a new standard of care in patients needing allogeneic hematopoietic cell transplantation.
In Part I: PTCy and Improved Outcomes, experts highlight the history of GVHD prevention and the impacts of post-transplant cyclophosphamide (PTCy) in particular in improving outcomes and closing gaps in access to care.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. -
08 - Returning to Work Post-HCT, Pt. 2: Communication and Resources to Overcome Barriers
In this two-part episode, Rachel Salit, MD, with Fred Hutch Cancer Center and Katie Schoeppner, MSW, of NMDP/Be The Match, discuss their recently developed evidence-based guidance for health care providers to assist patients in returning to work after hematopoietic cell transplantation as part of a committee of the American Society for Transplantation and Cellular Therapy (ASTCT).
In Part II: Communication and Resources to Overcome Barriers, experts dive deeper into the importance of multidisciplinary collaboration and communication across the care team, as well as resources to overcome barriers and evidence-based approaches to help patients return to work.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site. -
08 – Returning to Work Post-HCT, Pt. 1: Guidance Development and Challenges
In this two-part episode, Rachel Salit, MD, with Fred Hutch Cancer Center and Katie Schoeppner, MSW, of NMDP/Be The Match, discuss their recently developed evidence-based guidance for health care providers to assist patients in returning to work after hematopoietic cell transplantation as part of a committee of the American Society for Transplantation and Cellular Therapy (ASTCT).
In Part I: Guidance Development and Challenges, experts explore the complex challenges transplant patients face when returning to work and major findings from their evidence-based review, including the importance of appropriate accommodations, early communication with employers, and patient-reported outcomes.
To read bios on the panelists and to access additional resources related to this episode, visit Our Site.